Abbvie-Header Abbvie-Header

X

Find Oncology Drugs in Phase II Clinical Development in SWEDEN

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Melphalan Flufenamide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Pepaxto

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2021

            Details:

            The study demonstrates that for patients receiving melphalan flufenamide, also known as melflufen and dexamethasone in the phase 2 BRIDGE study, the exposure to melphalan increased with reduced eGFR similar to what is observed during treatment with melphalan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RV001

            Therapeutic Area: Oncology Product Name: RV001

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 08, 2021

            Details:

            RhoVac reported that as Covid-19 vaccinations are presently being rolled out in the age brackets of our study, some patients will have their RV001 treatment initiation deferred until after vaccination causing a delay in RhoVac's Phase IIb study.